Piero Galieni

4.4k total citations
89 papers, 1.7k citations indexed

About

Piero Galieni is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Piero Galieni has authored 89 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 48 papers in Hematology, 40 papers in Oncology and 35 papers in Molecular Biology. Recurrent topics in Piero Galieni's work include Multiple Myeloma Research and Treatments (35 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Lymphoma Diagnosis and Treatment (23 papers). Piero Galieni is often cited by papers focused on Multiple Myeloma Research and Treatments (35 papers), Chronic Lymphocytic Leukemia Research (23 papers) and Lymphoma Diagnosis and Treatment (23 papers). Piero Galieni collaborates with scholars based in Italy, Lebanon and United States. Piero Galieni's co-authors include S Tura, Michèle Cavo, Pier Luigi Zinzani, Ennio Polito, Alessandro Bucalossi, Antonio Leccisotti, Filíppo Gherlinzoni, Catia Bigazzi, Francesco Lauria and Michele Baccarani and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Piero Galieni

84 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Piero Galieni Italy 26 739 706 700 564 487 89 1.7k
Norifumi Tsukamoto Japan 25 826 1.1× 433 0.6× 706 1.0× 561 1.0× 381 0.8× 139 2.1k
Anne Lennard United Kingdom 20 414 0.6× 561 0.8× 831 1.2× 562 1.0× 218 0.4× 51 1.6k
Benet Nomdedeu Spain 22 881 1.2× 349 0.5× 592 0.8× 829 1.5× 361 0.7× 88 1.8k
Ho‐Jin Shin South Korea 22 944 1.3× 655 0.9× 691 1.0× 365 0.6× 399 0.8× 182 2.0k
Rudolf Schlag Germany 16 973 1.3× 1.0k 1.4× 669 1.0× 808 1.4× 871 1.8× 60 2.3k
Nicola Di Renzo Italy 24 531 0.7× 681 1.0× 944 1.3× 631 1.1× 329 0.7× 98 1.9k
Surender Juneja Australia 20 489 0.7× 375 0.5× 541 0.8× 538 1.0× 288 0.6× 85 1.3k
G. Pagnucco Italy 23 579 0.8× 486 0.7× 565 0.8× 589 1.0× 181 0.4× 69 1.4k
Rik Schots Belgium 15 1.1k 1.5× 999 1.4× 751 1.1× 446 0.8× 570 1.2× 37 2.0k
Maud Janvier France 20 918 1.2× 597 0.8× 382 0.5× 483 0.9× 500 1.0× 48 1.6k

Countries citing papers authored by Piero Galieni

Since Specialization
Citations

This map shows the geographic impact of Piero Galieni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Piero Galieni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Piero Galieni more than expected).

Fields of papers citing papers by Piero Galieni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Piero Galieni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Piero Galieni. The network helps show where Piero Galieni may publish in the future.

Co-authorship network of co-authors of Piero Galieni

This figure shows the co-authorship network connecting the top 25 collaborators of Piero Galieni. A scholar is included among the top collaborators of Piero Galieni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Piero Galieni. Piero Galieni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Filosa, Alessandra, et al.. (2022). Long‐term remission of extramedullary cutaneous relapse of acute myeloid leukaemia (leukaemia cutis) treated with decitabine‐venetoclax. SHILAP Revista de lepidopterología. 3(2). 517–520. 1 indexed citations
4.
5.
Bringhen, Sara, Roberto Mina, Maria Teresa Petrucci, et al.. (2019). Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies. Haematologica. 104(8). 1640–1647. 19 indexed citations
6.
Rigolin, Gian Matteo, Luca Formigaro, Lara Rizzotto, et al.. (2012). Chromosome aberrations detected by conventional karyotyping using novel mitogens in chronic lymphocytic leukemia with “normal” FISH: correlations with clinicobiologic parameters. Blood. 119(10). 2310–2313. 50 indexed citations
7.
Pagano, Livio, Caterina Giovanna Valentini, Valerio De Stefano, et al.. (2011). Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Annals of Oncology. 22(7). 1628–1635. 52 indexed citations
8.
Offidani, Massimo, Pietro Leoni, Laura Corvatta, et al.. (2010). ThaDD plus high dose therapy and autologous stem cell transplantation does not appear superior to ThaDD plus maintenance in elderly patients with de novo multiple myeloma. European Journal Of Haematology. 84(6). 474–483. 12 indexed citations
9.
Lemoli, Roberto M., Alessandra D’Addio, Giuseppe Marotta, et al.. (2009). BU/melphalan and auto-SCT in AML patients in first CR: a ‘Gruppo Italiano Trapianto di Midollo Osseo (GITMO)’ retrospective study. Bone Marrow Transplantation. 45(4). 640–646. 15 indexed citations
10.
Galieni, Piero, Pier Egisto Valensin, Daniele Laszlò, et al.. (2000). Human herpesvirus 6 infection in autologous bone marrow transplant recipients: A prospective study. Journal of Medical Virology. 60(1). 39–42. 7 indexed citations
11.
D’Elios, Mario Milco, Piero Galieni, Marianna Boncristiano, et al.. (1998). Expression of the T-Cell–Specific Tyrosine Kinase Lck in Normal B-1 Cells and in Chronic Lymphocytic Leukemia B Cells. Blood. 91(9). 3390–3396. 59 indexed citations
12.
Russo, Domenico, I Iacona, Stefano Sacchi, et al.. (1998). Time-Dependent Kinetics of Tretinoin in Chronic Myelogenous Leukaemia during Intermittent Dose Scheduling. Clinical Drug Investigation. 16(1). 25–33. 2 indexed citations
13.
Marinello, E., et al.. (1998). Isoenzymes of 5′-Nucleotidase in Human Lymphocytes. Advances in experimental medicine and biology. 431. 555–558.
14.
Polito, Ennio, Piero Galieni, & Antonio Leccisotti. (1997). Bilateral optic nerve compression caused by lymphomatous infiltration of all extraocular - muscles. Neuro-Ophthalmology. 17(1). 35–38. 1 indexed citations
15.
Polito, Ennio, Piero Galieni, & Antonio Leccisotti. (1996). Clinical and radiological presentation of 95 orbital lymphoid tumors. Graefe s Archive for Clinical and Experimental Ophthalmology. 234(8). 504–509. 65 indexed citations
16.
Galieni, Piero, Michèle Cavo, Giuseppe Avvisati, et al.. (1995). Solitary plasmacytoma of bone and extramedullary plasmacytoma: Two different entities?. Annals of Oncology. 6(7). 687–691. 67 indexed citations
17.
Tabucchi, Antonella, Roberto Pagani, M Pizzichini, et al.. (1995). Endo-5’-Nucleotidase Activity in Lymphocytes from Healthy Subjects and Leukemia Patients. Advances in experimental medicine and biology. 370. 231–235. 2 indexed citations
18.
Tura, S, Patrizio Mazza, Filíppo Gherlinzoni, et al.. (1989). Phase II study of a new alkylating agent (PTT-119) in resistant-relapsed non-Hodgkin's lymphomas. Cancer Chemotherapy and Pharmacology. 23(2). 123–5. 10 indexed citations
19.
Cavo, Michèle, Piero Galieni, Cristina Tassi, Marco Gobbi, & S Tura. (1988). M‐2 protocol for melphalan‐resistant and relapsing multiple myeloma. European Journal Of Haematology. 40(2). 168–173. 14 indexed citations
20.
Cavo, Michèle, Michele Baccarani, Piero Galieni, Marco Gobbi, & S Tura. (1986). Renal failure in multiple myeloma. A study of the presenting findings, response to treatment and prognosis in 26 patients.. PubMed. 28(3). 147–52. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Norifumi Tsukamoto Breakdown of academic impact, for papers by Anne Lennard Breakdown of academic impact, for papers by Benet Nomdedeu Breakdown of academic impact, for papers by Ho‐Jin Shin Breakdown of academic impact, for papers by Rudolf Schlag Breakdown of academic impact, for papers by Nicola Di Renzo Breakdown of academic impact, for papers by Surender Juneja Breakdown of academic impact, for papers by G. Pagnucco Breakdown of academic impact, for papers by Rik Schots Breakdown of academic impact, for papers by Maud Janvier
Rankless by CCL
2026